Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Yale School of Medicine researchers have discovered a protein that is the missing link in the complicated chain of events that lead to Alzheimer's disease, they report in the Sept. 4 issue of the journal Neuron. Researchers also found that blocking the protein with an existing drug can restore memory in mice with brain damage that mimics the disease.
"What is very exciting is that of all the links in this molecular chain, this is the protein that may be most easily targeted by drugs," said Stephen Strittmatter, the Vincent Coates Professor of Neurology and senior author of the study. "This gives us strong hope that we can find a drug that will work to lessen the burden of Alzheimer's."
Scientists have already provided a partial molecular map of how Alzheimer's disease destroys brain cells. In earlier work, Strittmatter's lab showed that the amyloid-beta peptides, which are a hallmark of Alzheimer's, couple with prion proteins on the surface of neurons. By an unknown process, the coupling activates a molecular messenger within the cell called Fyn.
In the Neuron paper, the Yale team reveals the missing link in the chain, a protein within the cell membrane called metabotropic glutamate receptor 5 or mGluR5. When the protein is blocked by a drug similar to one being developed for Fragile X syndrome, the deficits in memory, learning, and synapse density were restored in a mouse model of Alzheimer's.
Strittmatter stressed that new drugs may have to be designed to precisely target the amyloid-prion disruption of mGluR5 in human cases of Alzheimer's and said his lab is exploring new ways to achieve this.
Other Yale authors are Ji Won Um, Adam C. Kaufman, Mikhail Kostylev, Jacqueline K. Heiss, Massimiliano Stagi, Hideyuki Takahashi, Meghan E. Kerrisk, Alexander Vortmeyer, Thomas Wisniewski, Anthony J. Koleske, Erik C. Gunther and Haakon B. Nygaard.
The research was funded by the National Institutes of Health and the Falk Medical Research Trust. Strittmatter is co-founder of Axerion Therapeutics, seeking to develop therapeutics for Alzheimers.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Alzheimer's / Dementia category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Yale University. "Blocking mGluR5 can restore memory in mice with brain damage that mimics Alzheimer's." Medical News Today. MediLexicon, Intl., 9 Sep. 2013. Web.
6 Dec. 2013. <http://www.medicalnewstoday.com/releases/265740>
Yale University. (2013, September 9). "Blocking mGluR5 can restore memory in mice with brain damage that mimics Alzheimer's." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/265740.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.